

Disclosures

- I have received a research grant from SAGE for a project on CLABSI risk factors in the NICU (ended in 2015)
- Chair, National Advisory Committee on Immunization

Objectives

- Discuss why HCW need to be vaccinated
- Discuss potential impact of HCW's vaccination on later life protection
- Discuss/deal with impact of anti-vaccination messages



Convis

Université de Montréal

Why do we vaccinate? (A few principles

Objectives of vaccination programs depend on:

- 1. Efficacy/Effectiveness of available vaccines
- 2. Ability to reach target population
- 3. Epidemiology of disease

Program's objectives may be to:

- 1. Eradicate disease (e.g. smallpox)
- 2. Eliminate disease (i.e., no sustained transmission)

3. Control disease (i.e., no mortality/morbidity)

Herd immunity

- Infectious disease transmission is proportional to the % of susceptible individuals
- Transmission decreases with increase in protected people (vaccinated + recovered from disease).
- Proportion of protected people > 1 1/ R₀
- For measles $R_0 = 15$ requiring 94% of population to be protected to stop transmission



Why vaccina	te?				
	Possible measles exposure at MUHC Glen (adult) Site Pross Release				
	Apr 7, 2019				
	Text Size				
	MONTREAL — The McBI University Health Centre (MUHC) was notified by the Direction regionale de santé publique de Montréel alles Friday tibé an employee having contracted to the measles virus worked at the Girls Res while contraport. Jesuitem Natro 21 and Menth 27. The MUHC Is now in the process of identifying and informing all patients and personnel who worked in or valued the following locations during the hous personale block that them in how been enclosed to the measles which and the Moning locations during the hous personale block that them in how been enclosed to the measies which and the Moning locations during the hous personale block that them in how been enclosed to the measies which are during the measure which are the measure which are the measure which are personale to the process of the measure which are the measure which are the Moning location and the the measure which are the Moning location and the the measure which are the Moning location and the Moning location and the measure which are the Moning location and the measure which are the Moning location and the Moning location and the measure which are the Moning location and the Moning location and the Moning				
	Periods Periods Periods				
	Date of Exposure	Location	Location	Location	
	Saturday, March 23, 2019	10:00 - 11:00 D3-ICU	10:00 - 11:30 D7-Cardiac Surgery Unit		
	Sunday, March 24, 2019	10:00 - 11:00 D3-ICU	10:00 - 11:30 D7 - Cardiac Surgery Unit		
	Monday, March 25, 2019	7:45 - 8:45 D3-ICU	8:00 - 9:00 D7 - Candiac Surgery Unit		
	Tuesday, March 26, 2019	7:45 - 8:45 D3-ICU	8:00 - 9:00 D7 - Cardiac Surgery Unit	9 - 12:30 C.RC Cardiovascular, heart failure, heart transplant clinic	
Centre universitaire de santé McGill University Health Centre	Wednesday, March 27, 2019	10:00 -11:00 D2 - Infectious diseases clinic			



HCW vaccination

- HCW, including students, contract workers and volunteers: at risk of **exposure** to communicable diseases due to contact with patients
- Risk that HCW could **transmit** an undiagnosed vaccine-preventable disease to others
- Some healthcare institutions/jurisdictions: vaccination being a condition of employment

Vaccine	Recommendation(s)		
BCG	Consider use only in specified high-risk circumstances		
Diphtheria Tetanus	All HCW should be immune Primary series if no previous immunization Booster doses of Td vaccine every 10 years		
Hepatitis B	If no evidence of immunity 2		
Influenza	Annually		
Measles	if no evidence of immunity (refer to text), regardless of age - 2 doses		
Meningococcal	Not routinely for HCW Quadrivalent conjugate meningococcal vaccine for clinical laboratory workers who handle N. meningtitdlis specimens - 1 dose with a booster every 5 years if at ongoing risk		
Mumps	If no evidence of immunity (refer to text), regardless of age - 2 doses		
Pertussis	A single dose of Tdap vaccine if not previously received in adulthood.		
Polio	Primary series if no previous immunization - 3 doses. Unvaccinated HCW at highest risk of exposure should be particularly targeted for primary immunization. A single lifetime booster dose for HCW at highest risk of exposure.		
Rubella	If no evidence of immunity (refer to text) - 1 dose		
Travel vaccines	For HQW planning to work abroad, consider hapatitis A, cholera, Japanese encephalitis, tick-borne encephalitis, typhoid, and yellow fever vaccines prior to departure Revaccination for some vaccines if ongoing risk.		
March and March			

Influenza vaccination

Because it is needed every year... and is a daunting task!

té de médecine Université Maine de Montréal et du monde

11 =

Université de Montréal





HCW influenza vaccination

- Objective: Decrease influenza transmission from HCW to vulnerable patients
- How are we doing?
 - In Canada, without mandatory vaccination programs: 40-60%
 - If mandatory or vaccinate or mask: 95%
- · Is this the solution?



Influenza vaccine efficacy/effectiveness

- Efficacy (controlled setting i.e., RCT) vs. Effectiveness (real life)
- Are we talking 80-90% or 40-50%?
 - Depends on how it is measured.
 Older studies = seroconversion tends to overestimate VE
- Newer studies = viral culture and PCR (NAAT)
- Meta-analysis showed an average VE of:
 - 61% (A/H1N1)
 - 54% (B)
 - 33% (A/H3N2) → 80% admissions/ deaths

Université de Montréal et du m





What about HCW?

- Impossible to determine <u>who</u> patients catch influenza from
- Having HCWs protected is helpful
- RCTs (cluster) trying to show that an increase in vaccination coverage decreased nosocomial influenza failed to demonstrate impact (design issues)
- Nosocomial influenza:
 ONISP: 7% of 3299 cases (6 seasons)
 - FluSurv-NET: 2.7% of 6171 cases
- Estimated NNV to prevent one nosocomial infuenza death > 32 680
 Facult de médecier Université de Montréal et et montée







What does that all mean??

- Repeated influenza vaccination tends to decrease immune response and decrease VE
- <u>BUT</u>:

 It is hard to know AHEAD of the season if the interference will be positive (better VE) or negative
 It depends on the match between vaccine strains and circulating virus

11:

CHU Sala

Université de Montréal

Université de Montréal

• Given uncertainties, is it ethical to make vaccination mandatory?

Therefore...

- HCW should not work if sick or at least wear a mask and be highly compliant with hand hygiene
- Influenza vaccine will provide HCW with direct protection – variable VE ~ 50%
- Studies to determine role of HCW vaccination in herd immunity are needed (good studies) – it is likely that a protected HCW will protect patients

Hepatitis B: individual protection Table 1: Assessment of the causal link between needlestick injury and occupational infectious disease by diseas Hepatitis B Hepatitis C (n=2) (n=30) (n=2) (n=34) Causal link Likely Possible 1 21 9 2 0 24 10 Table 2: Serological finding of the initial test by disease Hepatitis B (n=2) Hepatitis C (n=30) HIV/AIDS (n=2) Total (n=34) 0 16 0 16 Initial finding* Negative Positive 2 3 0 5 Unknown 0 11 2 13 *Blood sampling within 5 days after the needlestick injury CHU Salare Justine Mentode and a second and a second de Mandre Faculté de médecine Université de Montréal e

	Initial ser	ological f	inding
	Negative/ Unknown	Positive	Total
	(n=29)	(n=5)	(n=34)
Activity			
Taking blood sample	5	0	5
Insertion/removal of catheter	5	0	5
During surgery (task unknown)	3	1	4
Insulin injection	1	0	1
Disposal of cannula (n=8), recapping (n=1)	9	0	9
Tidying up/waste disposal	4	0	4
Missing	2	4	6
Device			
Intravenous catheter, IV cannula	14	0	14
Suture needle, scalpel	2	1	3
Insulin pen ¹	1	0	1
Lancet ²	1	0	1
Type of cannula/type of instrument not stated	11	4	15
Index case			
Known	22	1	23
Missing	7	4	11

Hepatitis B vaccine

- Immunogenicity:
 - If anti-HBs titre at least 10 IU/L: considered protected for life (except immunocompromised and chronic renal disease)
 - Major determinant of seroprotection rates: age best when administered between 5-15 years, with gradual decrease with age.
- <u>Efficacy</u>
 - 95-100% effective in pre-exposure for at least 30 years.

Ø ∥≝

Course of

Université de Montréal

Measles: am I immune? Table 1: Criteria for measles immunity				
Routine immunization	Health care workers	Travellers to destinations outside North America	Students in post- secondary educational settings	Military personnel
Documentation of vaccination: C hildren 12 months to less than 18 years of age: 2 doses 11 Adults 18 years of age and older born in or after 1970: 1 dose 1, OR History of laboratory confirmed infection OR Laboratory evidence of immunity	Documentation of vaccination with 2 does 1 ⁻¹⁰ (regardless of year of birth) OR History of laboratory confirmed infection OR Laboratory evidence of immunity	Documentation of vaccination: • If born in or after 1970: 2 doese • If born before • 1970: 1 doese •	Documentation of vaccination: • If born in or after 1970: 2 doses • If born before 1970: contract 1970: contract 1970: contract 1970: contract 1970: contract 1970: contract of measles- containing vaccine OR History of laboratory confirmed infection OR Laboratory evidence of immunity	Dacumentation of vaccination with 2 does 1 (regardiess of year of birth) OR History of laboratory confirmed infection OR Laboratory evidence of immunity
Born before 1970				CIG, Evergreen

A question from my friend, Ramona R!

- How about serology testing: IgG on everyone upon employment?
 - Question of cost-effectiveness (for staff health)
 - If no documentation in doubt: vaccinate! Give the 2 doses of MMR
 - If some doubt remains: Measles IgG allowed... but as the medical director for the labs, cost matters... charged to your budget©.

Immune IF:

- Documented 2 doses of vaccine
- Laboratory evidence of immunity OR
- Self-reported history (healthy individuals, • including HCW) currently or previously employed in a Canadian healthcare setting IF disease happened before implementation of a 1-year VZ program (~ 2004)

CHU Salano-Jastine

Université de Montréal

Table 1: Implementation of one dose varicella immunization programs in canadian provinces and Territories				
Province or territory	Year of program implementation			
Prince Edward Island	2000			
Alberta	2001			
Northwest Territories	2001			
Nova Scotia	2002			
Nunavut	2002			
Ontario	2004			
New Brunswick	2004			
Manitoba	2004			
Newfoundland and Labrador	2005			
Saskatchewan	2005			
British Columbia	2005			
Quebec	2006			
Yukon	2007			

- For HCW, PPV of self- or parental reported disease:
 - 95% (range: 89-100%)
 - LR+ of reporting a history of VZ: 2.28

Recommendation #3: For HCWs who are currently employed in or who have been employed in another Canadian healthcare setting

Individuals who have ANY of the following are considered immune to varicella:

- Self-reported history or diagnosis of varicella or herpes zoster by a health care provider, if the disease occurred before the year of implementation of a varicella vaccine program (one dose) (Grade B);
 Documented vedence of immunization with two doses of a varicella-containing vaccine (Grade A);
 Previous laboratory evidence of varicella immunity III (Grade A)

New employment in a healthcare setting (i.e. Canadian HCW moving into a new facility within Canada) should be seen as an opportunity to assess immunity to varicella and to offer two doses of varicella vaccine when the HCW has not been hown to be immune.

Following exposure to varicella within health care settings, verification of immunity, based on documented evidence of immunization with two doses of a varicella-containing vaccine or laboratory evidence of immunity, should be a part of post-exposure protocols.

de Montreal et du monde cititatione scalanne 2011/2011 NACI

ecommendation #4: For HCWs who are newly hired into the Canadian healthcare system ndividuals who have ANY of the following are considered immune to varicella:

Previous laboratory evidence of varicella immunity b (Grade A).

st-exposure protocols.

ave vaccination offered post-partum (Grade A).

Documented evidence of immunization with two doses of a varicella-containing vaccine (Grade A):

Following exposure to varicella within health care settings, verification of immunity, based on documented evidence of immunization with two doses of a varicella-containing vaccine or laboratory evidence of immunity, should be a part o

tecommendation #5: Immunization should be offered to all susceptible individuals without contraindications to aricella vaccination. Pregnant women who are not considered immune to varicella (as per Recommendation #1) shou

Another question from my friend, Ramonal

- «We are seeing a lot of disseminated zosters, here too why are HCW not asked for proof of immunity for varicella (IgG)....!!! It is much cheaper than having to do exposures, work late hours, deal with worried patients and staff and rush IgG.... »
- · She is right!
- To deal with exposures, should know BEFORE HCW's status. Need a good pre-employment screening.
- In doubt, just vaccinate!

11:

Université de Montréal

What to do about vaccine hesitancy?

- Difference between anti-vaxxers and vaccine hesitants
- To overcome cynicism, be transparent there are things we don't know. What we know, we disclose
- The overall objective of vaccination is to protect HCW and patients
- Vaccines are not risk-free: like a medication. Goal is for **benefits to outweigh risks**
- Critical review of evidences

Take home messages

- HCW vaccination is important to:
 - PROTECT HCWs from infections they may encounter in their daily work
 PROTECT patients they care for
- Influenza: we need a better vaccine
 - Yet, it is our responsibility to be vaccinated
 - HCW influenza vaccination should not become mandatory

